Category: 15456-86-7

Synthetic Route of 15456-86-7, Because a catalyst decreases the height of the energy barrier, its presence increases the reaction rates of both the forward and the reverse reactions by the same amount.15456-86-7, Name is 4-Bromo-1,2-dihydropyridazine-3,6-dione, molecular formula is C4H3BrN2O2. In a article£¬once mentioned of 15456-86-7

Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors

New pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs were synthesized and their inhibitory activities against DYRK1A, CDK5/p25, GSK3alpha/beta and p110-alpha isoform of PI3K evaluated using harmine as reference. Both furan-2-yl 10 and pyridin-4-yl 19 from the two different series, exhibited submicromolar IC50 against DYRK1A with no activities against the three other kinases. In addition, compound 10 exhibited antiproliferative activities in the Huh-7, Caco2 and MDA-MB-231 cell lines.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 15456-86-7

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2804 – PubChem

 

Chemistry is an experimental science, and the best way to enjoy it and learn about it is performing experiments. Recommanded Product: 4-Bromo-1,2-dihydropyridazine-3,6-dione. Introducing a new discovery about 15456-86-7, Name is 4-Bromo-1,2-dihydropyridazine-3,6-dione

TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS

Tricyclic nitrogen containing compounds and their use as antibacterials. Z1and Z2 are independently selected from CH and N.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Recommanded Product: 4-Bromo-1,2-dihydropyridazine-3,6-dione, you can also check out more blogs about15456-86-7

Reference£º
Pyridazine – Wikipedia,
Pyridazine | C4H4N2791 – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.15456-86-7,4-Bromo-1,2-dihydropyridazine-3,6-dione,as a common compound, the synthetic route is as follows.

c) 3,4,6-Trichloropyridazine; This was prepared by a slight variation on the method of Kasnar et al, Nucleosides & Nucleotides (1994), 13(1-3), 459-79.Hydrazine sulphate salt (51 g) was suspended in water (250 ml), heated to reflux and bromomaleic anhydride (90.38 g) was added dropwise. The mixture was heated at reflux for 4 hours then cooled to room temperature. The reaction was repeated with 29 g hydrazine sulphate, 53 g bromomaleic anhydride and 130 ml water. The precipitates were collected by filtration, washed with water and acetone and dried as a combined batch in vacuo to afford 4-bromo-1,2-dihydro-3,6-pyridazinedione as a white solid (113 g). The solid in two batches was treated with phosphorus oxychloride (2¡Á200 ml) and heated to reflux for 3.5 hours. The mixture was cooled, evaporated and azeotroped with toluene. The residue was partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution and extracted with DCM twice more. The organic extracts were dried and evaporated. This residue was re-dissolved in dichloromethane, and chromatographed on silica gel (300 g) (DCM as eluent) to give a white solid (101.5 g, 87%).(LC-MS analysis showed ca 20-30% impurity, isomers of bromo-dichloropyridazine).MS (+ve ion electrospray) m/z 184/185/186 (MH+), trichloropyridazine.MS (+ve ion electrospray) m/z 228/229/231 (MH+), bromo-dichloropyridazine.

15456-86-7, As the paragraph descriping shows that 15456-86-7 is playing an increasingly important role.

Reference£º
Patent; GLAXO GROUP LIMITED; US2010/56502; (2010); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

 

15456-86-7, 4-Bromo-1,2-dihydropyridazine-3,6-dione is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

b 4-Bromo-3,6-dichloropyridazine A solution of 4-bromo-1,2-dihydropyridazine-3,6-dione (10 g, 52 mmol) in phosphorus oxychloride (100 ml) was stirred and heated at 100 C. under nitrogen for 16 h. Upon cooling the excess phosphorus oxychloride was removed in vacuo. The residue was azeotroped with toluene (*2), then taken up in dichloromethane/water. The mixture was carefully basified with sodium hydrogen carbonate (solid). It was necessary to dilute the mixture further to get two clear layers. The two layers were separated and the aqueous was extracted with dichloromethane (*3). The combined extracts were dried (Na2SO4), filtered and evaporated. The residue was purified by chromatography on silica gel, eluding with dichloromethane to afford the title pyridazine (5.0 g, 42%) as a colourless solid. 1H NMR (250 MHz, CDCl3) 7.68 (br s). MS (ES30) 230 [MH]+, 228 [MH]+.

15456-86-7, 15456-86-7 4-Bromo-1,2-dihydropyridazine-3,6-dione 254942, apyridazine compound, is more and more widely used in various fields.

Reference£º
Patent; Merck Sharp & Dohme Limited; US6291460; (2001); B1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

 

15456-86-7, 4-Bromo-1,2-dihydropyridazine-3,6-dione is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a degassed solution of 4-bromo-1,2-dihydropyridazine-3,6-dione (100 mg, 0.5 mmol), (4-fluoro-1H-indol-2-yl)boronic acid (131 mg, 0.7 mmol) and K3P04 (279 mg, 1.1 mmol) in DMF (2 mL) and H20 (0.2 mL) was added Pd(dppf)Cl2 (5 mg) under N2. The mixture was stirred at 80 C for 12 h. After the solvent was removed, the residue was purified by prepTLC (DCM : EtOAc = 10: 1) to give the product of 4-(4-fluoro-1H-indol-2-yl)-1,2-dihydropyridazine-3,6-dione (50 mg, yield: 39%). ?H-NMR (DMSO-d6, 400 MHz,) 11.95 (br.s, 1H), 7.47-7.68 (m, 3H), 7.35 (d, J= 8.0 Hz, 1H), 7.1 1-7.19 (m, 1H), 6.81 (dd, J= 8.0, 10.4Hz, 1H). MS (M+H): 246., 15456-86-7

The synthetic route of 15456-86-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; DAI, Xing; LIU, Hong; PALANI, Anandan; HE, Shuwen; BROCKUNIER, Linda, L.; NARGUND, Ravi; MARCANTONIO, Karen; ZORN, Nicolas; XIAO, Dong; PENG, Xuanjia; LI, Peng; GUO, Tao; WO2014/123793; (2014); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.15456-86-7,4-Bromo-1,2-dihydropyridazine-3,6-dione,as a common compound, the synthetic route is as follows.

The solid, divided into two batches, was treated with phosphorus oxychloride (2×200 ml) and heated to reflux for 3.5 h. The mixture was cooled, evaporated and azeotroped with toluene. The residue was partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution and extracted with DCM twice more. The organic extracts were dried and evaporated. This residue was re-dissolved in dichloromethane, and chromatographed on silica gel (300 g) (DCM as eluent) to give a white solid (101.5 g, 87%). (LC/MS analysis showed ca. 20-30% impurity, isomers of bromo-dichloropyridazine)., 15456-86-7

The synthetic route of 15456-86-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2008/6648; (2008); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

 

15456-86-7, 4-Bromo-1,2-dihydropyridazine-3,6-dione is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Essentially as previously described (/. Neuroinflamm. 2007, 4, 21 ; herein incorporated by reference in its entirety), compound 1-1 (2 g, 10.4 mmol, 1 eq) and pyridin-4-yI boronic acid (14,3 mmol, 1.76 g, 1.37 eq) were suspended in dimeihoxyeihane and water (10: 1 v/v) in a heavy wall pressure vessel and purged with argon for 15 min. Tetrakis(triphenylphosphine)palladium (0.1 eq) and sodium carbonate (3eq) were added, the vessel immediately capped, the reaction mixture heated (1 10 C ) for 18 h, then cooled to ambient temperature and subjected to filtration on a medium frit sintered glass funnel containing Ceiite 545. The filtrate was concentrated in vacuo and the concentrate triturated with hexane. The yellow product 1 -2 (2.2 g) exhibited a mass (ESI) of m/z (MeOH) =190.06 (MET), and was taken to the next step without further purification., 15456-86-7

As the paragraph descriping shows that 15456-86-7 is playing an increasingly important role.

Reference£º
Patent; THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK; ARANCIO, Ottavio; WATTERSON, Daniel, Martin; PELLETIER, Jeffrey, Claude; ROY, Saktimayee, Mitra; WO2014/145485; (2014); A2;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.15456-86-7,4-Bromo-1,2-dihydropyridazine-3,6-dione,as a common compound, the synthetic route is as follows.

The solid in two batches was treated with phosphorus oxychloride (2×200 ml) and heated to reflux for 3.5 h. The mixture was cooled, evaporated and azeotroped with toluene. The residue was partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution and extracted with DCM twice more. The organic extracts were dried and evaporated. This residue was re-dissolved in dichloromethane, and chromatographed on silica gel (300 g) (DCM as eluent) to give a white solid (101.5 g, 87%). (LC/MS analysis showed ca. 20-30% impurity, isomers of bromo- dichloropyridazine).MS (+ve ion electrospray) m/z 184/185/186 (MH+), trichloropyridazineMS (+ve ion electrospray) m/z 228/229/231 (MH+), bromo-dichloropyridazine.

15456-86-7, 15456-86-7 4-Bromo-1,2-dihydropyridazine-3,6-dione 254942, apyridazine compound, is more and more widely used in various fields.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2007/115947; (2007); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem